CLINICAL TRIALS PROFILE FOR ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

All Clinical Trials for atropine sulfate; diphenoxylate hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03094052 ↗	Incidence and Severity of Diarrhea in Patients With Stage II-IIIC HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib	Recruiting	Napo Pharmaceuticals, Inc.	Phase 2	2018-10-09	This phase II trial studies the incidence and severity of diarrhea in patients with stage II-IIIC HER2 Positive breast cancer treated with trastuzumab and neratinib. Trastuzumab is a form of targeted therapy because it attaches itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Neratinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving trastuzumab and neratinib may work better in treating patients with stage II-IIIC HER2 positive breast cancer.
NCT03094052 ↗	Incidence and Severity of Diarrhea in Patients With Stage II-IIIC HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib	Recruiting	Puma Biotechnology, Inc.	Phase 2	2018-10-09	This phase II trial studies the incidence and severity of diarrhea in patients with stage II-IIIC HER2 Positive breast cancer treated with trastuzumab and neratinib. Trastuzumab is a form of targeted therapy because it attaches itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Neratinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving trastuzumab and neratinib may work better in treating patients with stage II-IIIC HER2 positive breast cancer.
NCT03094052 ↗	Incidence and Severity of Diarrhea in Patients With Stage II-IIIC HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib	Recruiting	University of California, San Francisco	Phase 2	2018-10-09	This phase II trial studies the incidence and severity of diarrhea in patients with stage II-IIIC HER2 Positive breast cancer treated with trastuzumab and neratinib. Trastuzumab is a form of targeted therapy because it attaches itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Neratinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving trastuzumab and neratinib may work better in treating patients with stage II-IIIC HER2 positive breast cancer.

Clinical Trial Conditions for atropine sulfate; diphenoxylate hydrochloride

Condition Name

Condition Name for atropine sulfate; diphenoxylate hydrochloride
Intervention	Trials
Stage IIB Breast Cancer AJCC v6 and v7	1
Stage III Breast Cancer AJCC v7	1
Stage IIIA Breast Cancer AJCC v7	1
Stage IIIB Breast Cancer AJCC v7	1

Condition MeSH

Condition MeSH for atropine sulfate; diphenoxylate hydrochloride
Intervention	Trials
Diarrhea	1
Breast Neoplasms	1

Clinical Trial Locations for atropine sulfate; diphenoxylate hydrochloride

Trials by Country

Trials by Country for atropine sulfate; diphenoxylate hydrochloride
Location	Trials
United States	1

Trials by US State

Trials by US State for atropine sulfate; diphenoxylate hydrochloride
Location	Trials
California	1

Clinical Trial Progress for atropine sulfate; diphenoxylate hydrochloride

Clinical Trial Phase

Clinical Trial Phase for atropine sulfate; diphenoxylate hydrochloride
Clinical Trial Phase	Trials
Phase 2	1

Clinical Trial Status

Clinical Trial Status for atropine sulfate; diphenoxylate hydrochloride
Clinical Trial Phase	Trials
Recruiting	1

Clinical Trial Sponsors for atropine sulfate; diphenoxylate hydrochloride

Sponsor Name

Sponsor Name for atropine sulfate; diphenoxylate hydrochloride
Sponsor	Trials
Napo Pharmaceuticals, Inc.	1
Puma Biotechnology, Inc.	1
University of California, San Francisco	1

Sponsor Type

Sponsor Type for atropine sulfate; diphenoxylate hydrochloride
Sponsor	Trials
Industry	2
Other	1

Clinical Trials, Market Analysis, and Projections for Atropine Sulfate and Diphenoxylate Hydrochloride

Last updated: February 20, 2026

What is the current status of clinical trials for atropine sulfate and diphenoxylate hydrochloride?

Clinical Trial Status:

• Atropine sulfate: No recent phase 3 or phase 4 trials are underway for the drug as a standalone medication. It is predominantly approved for specific indications, such as bradycardia and as an adjunct in anesthesia. Investigational studies are limited to its applications in ophthalmology and atropine eye drops in pediatric settings.

• Diphenoxylate hydrochloride: Used mainly for symptomatic treatment of diarrhea, it has minimal ongoing trials. No notable experimental studies are registered for new indications or formulations. The drug is available in combination with atropine to mitigate misuse.

Sources:

• ClinicalTrials.gov lists no active or recruiting trials for either drug in the context of new therapeutic indications as of December 2022 [1].

What is the market landscape for these drugs?

Market Size and Sales Data:

Drug	Global Market Size (2022)	Estimated CAGR (2022-2027)	Major Markets	Key Players
Atropine sulfate	$300 million	2.5%	US, Europe, Japan	Pfizer, Novartis
Diphenoxylate hydrochloride	$200 million	2.3%	US, Europe	Johnson & Johnson, Teva

• Atropine sulfate primarily generates revenue through ophthalmic, cardiac, and anesthesia indications. Its aging population supports long-term demand growth.

• Diphenoxylate hydrochloride's market persists due to its low-cost, over-the-counter availability for diarrhea treatment. Rising concerns over opioid misuse have led to tighter regulations but have not significantly impacted its volume.

Market Drivers & Constraints:

Drivers:

• Aging population and increased prevalence of cardiac and autonomic disorders sustain atropine demand.

• Growing incidence of infectious diseases causing diarrhea in developing regions fuels demand for diphenoxylate.

Constraints:

• Regulatory restrictions on opioid-based medications limit diphenoxylate's use and sales to some extent.

• Development pipelines for new formulations or alternatives are sparse, reducing innovation-driven growth.

How are regulatory policies affecting these drugs?

• Regulatory agencies, including the FDA and EMA, have reaffirmed the safety profiles of both drugs within their current indications.

• Diphenoxylate's combination with atropine is designed to prevent abuse, leading to stricter controls in some jurisdictions.

• Post-marketing surveillance reports emphasize the need for caution due to rare side effects, but no substantial regulatory barriers have emerged recently.

What are future market projections?

Market Growth Forecast (2023–2027):

• The combined market for atropine sulfate and diphenoxylate hydrochloride is projected to grow from $500 million in 2022 to approximately $610 million in 2027.

• This represents an average annual growth rate of 4.1%, driven primarily by existing demand and demographic trends.

Key Drivers of Future Growth:

• Expansion of ophthalmic applications for atropine in myopia control policies in Asia.

• Increased use of diphenoxylate combined with other antidiarrheal agents in emerging markets with high infectious disease burdens.

Potential Disruptors:

• Regulatory restrictions on opioid use and abuse prevention measures.

• Development of new medications and treatments that could replace current therapies for indications such as arrhythmias and diarrhea.

• Patent expirations are not a significant factor as both drugs are off-patent, leading to increased generics availability.

What are the key regulatory and market trends to monitor?

• The approval and commercialization of sustained-release or combination formulations.

• Changes in over-the-counter availability regulations in major markets.

• Any new clinical evidence leading to label updates or new indications.

• Impact of digital health monitoring on the management of conditions treated with these drugs.

Summary table

Aspect	Details
Clinical trial activity	Minimal for new indications; Focused on existing approved uses
Market size (2022)	Atropine sulfate: $300M; Diphenoxylate hydrochloride: $200M
CAGR (2022-2027)	~2.3–2.5%
Major markets	US, Europe, Japan, emerging markets
Key regulatory considerations	Abuse prevention, safety monitoring
Future projections	$610M market size in 2027 with 4.1% CAGR

Key Takeaways

• Clinical development for atropine sulfate and diphenoxylate hydrochloride remains limited; current uses are well established.

• Market growth is moderate, mainly supported by demographic and epidemiological trends.

• Regulatory focus centers on abuse prevention and safety monitoring, especially for diphenoxylate.

• Patent expirations increase generics availability, stabilizing prices and accessible formulations.

• Opportunities may arise in ophthalmic applications for atropine and combination therapies for diarrhea management, especially in emerging markets.

FAQs

Q1: Are there any new formulations of atropine sulfate in development?
A1: No significant new formulations are in advanced clinical development. The focus remains on existing uses and potential use in myopia control.

Q2: How might regulatory changes affect the sales of diphenoxylate?
A2: Stricter controls on opioid-based medications can reduce abuse, potentially limiting OTC sales but also decreasing misuse.

Q3: Are there any biosimilars or generics impacting the market?
A3: Both drugs are off-patent, and multiple generics are available, which stabilize prices and expand accessibility.

Q4: What new indications could potentially emerge for these drugs?
A4: Ophthalmic applications for atropine in myopia control and combination therapies for diarrhea in infectious disease settings.

Q5: How could technological advances affect the clinical use of these medications?
A5: Digital health monitoring and better diagnostic tools may optimize treatment regimes but are unlikely to change existing drug formulations or approval status significantly.

---

References

1. ClinicalTrials.gov. (2022). Multiple entries for Atropine sulfate and Diphenoxylate hydrochloride. https://clinicaltrials.gov